HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

JNJ-26483327

an orally active macrocyclic tyrosine kinase inhibitor for treatment of patients with advanced solid tumours; in Phase I trial, 9/2010

Also Known As:

MTKi-327

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - JNJ-26483327: 2

Experts

1.	Arien, Tina: 1 article (09/2014)
2.	Brewster, Marcus E: 1 article (09/2014)
3.	Danhier, Fabienne: 1 article (09/2014)
4.	Préat, Véronique: 1 article (09/2014)
5.	Ucakar, Bernard: 1 article (09/2014)
6.	Vanderhaegen, Marie-Lyse: 1 article (09/2014)
7.	Burger, H: 1 article (09/2010)
8.	Eskens, F A L M: 1 article (09/2010)
9.	Hellemans, P: 1 article (09/2010)
10.	Konings, I R H M: 1 article (09/2010)

Related Diseases

1.	Neoplasms (Cancer) 09/28/2010 - "Nineteen patients with advanced cancers received JNJ-26483327 continuous twice daily (BID) in escalating dose cohorts ranging from 100 to 2100 mg. Pharmacodynamic effects were assessed in paired skin biopsies and blood. " 09/01/2014 - "Nanosuspension may be considered as an effective anti-cancer MTKi-327 delivery method due to (i) the higher MTKi-327 maximum tolerated dose, (ii) the possible intravenous injection of MTKi-327, (iii) its ability to enhance the administered dose and (iv) its higher efficacy." 09/01/2014 - "Hence, the aims of this work were (i) to evaluate the MTKi-327 nanosuspension for parenteral and oral administrations and (ii) to compare this nanosuspension with other nanocarriers in terms of anti-cancer efficacy and pharmacokinetics. " 09/01/2014 - "We hypothesized that nanosuspensions could be promising for the delivery of the poorly water soluble anti-cancer multi-targeted kinase inhibitor, MTKi-327. "
2.	Vomiting 09/28/2010 - "JNJ-26483327 was well tolerated in doses up to 1500 mg BID, with target-inhibition-related toxicity such as diarrhoea and skin rash, and other common reported toxicities being nausea, vomiting, anorexia and fatigue. "
3.	Nausea 09/28/2010 - "JNJ-26483327 was well tolerated in doses up to 1500 mg BID, with target-inhibition-related toxicity such as diarrhoea and skin rash, and other common reported toxicities being nausea, vomiting, anorexia and fatigue. "
4.	Fatigue 09/28/2010 - "JNJ-26483327 was well tolerated in doses up to 1500 mg BID, with target-inhibition-related toxicity such as diarrhoea and skin rash, and other common reported toxicities being nausea, vomiting, anorexia and fatigue. "
5.	Exanthema (Rash) 09/28/2010 - "JNJ-26483327 was well tolerated in doses up to 1500 mg BID, with target-inhibition-related toxicity such as diarrhoea and skin rash, and other common reported toxicities being nausea, vomiting, anorexia and fatigue. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)

Related Therapies and Procedures

1.	Intravenous Injections
2.	Oral Administration